BioAtla Inc Reports Q2 2024 Financial Results
Intellectia.AI Updated: 1970-01-01
BioAtla, Inc. Reports Q2 2024 Financial Results
San Diego, CA – BioAtla, Inc. (Nasdaq: BCAB), a clinical-stage biopharmaceutical company, today announced its financial results for the second quarter ended June 30, 2024.
Key Financial Metrics
| Metric | Q2 2024 | Q2 2023 | YoY Change | Consensus Estimates | Q1 2024 | QoQ Change |
|---|---|---|---|---|---|---|
| Total Revenue | $0.00 million | $0.00 million | 0% | Not provided | $0.00 million | 0% |
| Earnings Per Share (EPS) | ($0.44) | ($0.74) | 40.5% | ($0.44) | ($0.61) | 27.9% |
| Net Loss | $21.1 million | $35.8 million | 41.1% | Not provided | $23.2 million | 9.1% |
BioAtla's financial performance improved year over year (YoY), with a notable reduction in net loss and an EPS that aligned with Wall Street's consensus estimates for the current quarter. The company's financial losses have also decreased quarter over quarter (QoQ) compared to Q1 2024.
Comments from Company Officers
Management highlighted that even though BioAtla did not generate revenue in the second quarter, significant progress was made in cost management and research advancements. The company continues to focus on advancing its clinical development programs.
Dividends and Share Repurchase Program
No dividends or share repurchase were announced in this quarter’s financial report.
Forward Guidance
BioAtla did not provide explicit forward guidance for the following quarters. However, the company remains focused on achieving key milestones in clinical development and regulatory reviews.
Stock Price Movement
Post-earnings release, BioAtla’s stock experienced an increase of approximately 5.76%, reflecting investor optimism on continued operational improvements and cost management efforts.
For further details, please refer to BioAtla's complete quarterly report on Form 10-Q filed with the SEC.
[End of Summary]